Expert Interview
Examining the potential of BioNTech/DualityBio' DB-1303 in patients with advanced/metastatic solid tumors after receiving fast track designation
Ticker(s): BNTX, Duality BioInstitution: Moffitt Cancer Center
- Gastrointestinal Oncology, Medical Oncology, and Associate Member, GI Medical Oncology.
- Currently manages 30-35 patients with ESCC per year and 8-10 patients per month with HER2 solid tumors ~ gastroesophageal cancers exclusively.
- Clinical interests are a spectrum of gastrointestinal cancers including esophageal, gastric, hepato-biliary, pancreatic and colorectal cancers, both early stages and advanced stages.
- Research interests are primarily esophageal/gastric cancers and colon cancer with an interest in bringing basic research to the clinic by developing innovative clinical trials for patients.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
